Latest Tax Incentives News

Terragen Holdings reports robust quarterly progress, highlighted by successful beef feedlot trials and a $4.76 million equity raise, setting the stage for its new probiotic product launch in March 2025.

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.

Identitii reports solid quarterly progress highlighted by a strategic new director appointment, US market expansion, and a successful $1.8 million capital raise, underpinning its path toward profitability.

FBR Limited has successfully completed its US Demonstration Program with CRH Ventures, raising $8 million through a Share Purchase Plan and positioning itself for a significant joint venture in the US construction robotics market.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Tivan Limited has advanced its Speewah Fluorite Project with a $7.4 million government grant and Major Project Status, alongside a joint venture MoU with Sumitomo Corporation and promising drilling results at Sandover.

Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.

Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

Omega Oil and Gas Limited has successfully raised A$7 million in a strongly supported institutional placement, positioning the company to advance its Canyon-1H fracture stimulation and appraisal program.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.